Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
ANIP · Nasdaq · United States · Pharmaceutical Preparations
In shortANI PHARMACEUTICALS INC is profitable, generates cash and carries moderate debt, with revenue growing (+43.8% last year).
Financial health
Solid
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 12.6% | 59/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 8.9% | 55/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 16.6% | 83/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 10.7% | 71/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 2.71× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.57× | 79/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 0.12× | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 3.41× | 18/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 3.26 | 55/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 19.4% | 98/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 2.19× | 100/100 |
| Years with positive free cash flow (last 5) | 4 of 5 | 75/100 |
Weight in the score: 20%
| Profitable years (last 5) | 2 of 5 | 40/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 20.1% | 37/100 |
| Operating margin volatility | 13.3% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 40.8% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 216 | 316 | 487 | 614 | 883 |
| Research & development | 11 | 22 | 34 | 45 | 52 |
| Selling, general & admin | 84 | 124 | 162 | 250 | 318 |
| Operating income | (40) | (35) | 47 | 0.6 | 111 |
| Interest expense | 12 | 29 | 36 | 34 | 33 |
| Pre-tax income | (56) | (63) | 20 | (22) | 96 |
| Income tax | (13) | (15) | 1.1 | (3.7) | 17 |
| Net income | (43) | (48) | 19 | (19) | 78 |
| Diluted EPS | −$3.40 | −$3.05 | $0.85 | −$1.04 | $3.32 |
| Diluted shares (millions) | 13 | 16 | 18 | 19 | 21 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 8 reported quarters (10-Q and 10-K filings), in USD millions. The fourth quarter is derived from the annual report.
The last 8 quarters of ANI PHARMACEUTICALS INC are included in the Investor plan. Try free for 7 days →
3.26 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
6/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 7, 2026